Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.51 |
| ▸ | CSNK1D | P48730 | 14/20 | 0.51 |
| ▸ | ACP1 | P24666 | 1/20 | 0.47 |
| ▸ | NCS1 | P62166 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.44 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.44 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19612122 | 0.87 | DYRK1A (0.57) | DYRK1ACSNK1DACP1NCS1CYP2D6 | |
| SCHEMBL19630768 | 0.85 | CSNK1D (0.55) | DYRK1ACSNK1DACP1NCS1LRRK2 | |
| SCHEMBL24044916 | 0.84 | DYRK1A (0.54) | DYRK1ACSNK1DACP1NCS1CYP2D6 | |
| SCHEMBL19612108 | 0.84 | DYRK1A (0.54) | DYRK1ACSNK1DACP1NCS1CYP2D6 | |
| SCHEMBL19612165 | 0.83 | DYRK1A (0.53) | DYRK1ACSNK1DACP1NCS1CYP2D6 | |
| SCHEMBL19612166 | 0.83 | DYRK1A (0.53) | DYRK1ACSNK1DACP1NCS1CYP2D6 | |
| SCHEMBL19627267 | 0.83 | DYRK1A (0.53) | DYRK1ACSNK1DACP1NCS1CYP2D6 | |
| SCHEMBL19630916 | 0.83 | KMT2A (0.43) | NCS1CASP3SENP8SENP7SENP6 | |
| SCHEMBL19630998 | 0.82 | CSNK1D (0.50) | DYRK1ACSNK1DACP1NCS1CYP2D6 | |
| SCHEMBL19612156 | 0.82 | CSNK1D (0.50) | DYRK1ACSNK1DACP1NCS1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10227315-B2 | Mitochondrial uncouplers for treatment of metabolic diseases and cancer | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2019-03-12 | — | — | US | disclosed |
| US-20170334869-A1 | NOVEL MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC DISEASES AND CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227315-B2 | Mitochondrial uncouplers for treatment of metabolic diseases and cancer | AK2, PC, GLS2 | DYRK1A 4412/4885CSNK1D 3205/4885ACP1 1398/4885 |
| US-20170334869-A1 | NOVEL MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC DISEASES AND CANCER | AK2, PC, GLS2 | DYRK1A 4289/4885CSNK1D 3164/4885ACP1 1257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.